tirzepatide vs dulaglutide Cardiovascular Outcomes with Compared with in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Tirzepatide: A Promising Drug for

We present a detailed picture showing that epithelial-to-mesenchymal transition, cancer metabolic reprogramming, alterations in important signalling pathways, epigenetic aberrations and the tumour microenvironment are crucial drivers of PTC metastasis

new longevity drugs just dropped on immortals rx microdose GLP-1s peptides NAD+ etc

Retatrutide, as the newest and most advanced triple-agonist metabolic peptide, sits at the higher end of the research peptide pricing range but the gap between the cheapest Canadian retatrutide and the most

GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors, according to data presented at the EULAR 2025 Congress.“Our aim was to investigate whether GLP-1 receptor agonists could have a protective effect for the treatment of RA patients on JAK inhibitors to reduce cardiovascular

Excited to share my recent certification in () through GxP training

As patents for Semaglutide begin to expire, we are moving from a period of high-cost exclusivity to a new era of mass accessibility